Reason for request
First listing
Summary of opinion
Favourable opinion for reimbursement only “as an add-on to standard therapy, including first-line immunosuppressants, for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive, who remain symptomatic.”
Unfavourable opinion for reimbursement in the other situations covered by the MA indication.
Clinical Benefit
| Substantial |
The clinical benefit of RYSTIGGO (rozanolixizumab) is substantial only as an add-on to standard therapy, including first-line immunosuppressants, for the treatment of generalised myasthenia gravis (gMG) in adultpatients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive, who remain symptomatic.
|
See also
HAS opinions and decisions
03/05/2024
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
4HLvxgQrnYSBxq6P
